share_log

DaVita | 8-K: Current report

DaVita | 8-K: Current report

德維特 | 8-K:重大事件
美股SEC公告 ·  2024/09/14 04:18

Moomoo AI 已提取核心訊息

DaVita announced the appointment of David P. Maughan as Chief Operating Officer of DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri who will transition to Chief Operating Officer Emeritus. Maughan, 47, previously served as Senior Vice President, Kidney Care, overseeing national home and hospital services businesses since November 2019.Under the new employment agreement, Maughan will receive an annual base salary of $725,000 and a target incentive bonus opportunity of 100% of his 2024 base salary. He will participate in the company's employee benefit plans and long-term incentive programs available to senior executives.The agreement includes severance provisions for termination without cause or resignation for good cause, including base salary continuation for one year (extending to two years if resignation occurs within 60 days following a good cause event within two years of a change in control). Prior to joining DaVita in 2006, Maughan worked at Goldman Sachs in Finance from 2001 to 2004.
DaVita announced the appointment of David P. Maughan as Chief Operating Officer of DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri who will transition to Chief Operating Officer Emeritus. Maughan, 47, previously served as Senior Vice President, Kidney Care, overseeing national home and hospital services businesses since November 2019.Under the new employment agreement, Maughan will receive an annual base salary of $725,000 and a target incentive bonus opportunity of 100% of his 2024 base salary. He will participate in the company's employee benefit plans and long-term incentive programs available to senior executives.The agreement includes severance provisions for termination without cause or resignation for good cause, including base salary continuation for one year (extending to two years if resignation occurs within 60 days following a good cause event within two years of a change in control). Prior to joining DaVita in 2006, Maughan worked at Goldman Sachs in Finance from 2001 to 2004.
德維特宣佈任命David P. Maughan爲德維特腎臟護理的首席運營官,任命自2024年9月15日起生效,接替Michael D. Staffieri,後者將過渡爲名譽首席運營官。47歲的Maughan在2019年11月之前擔任腎臟護理的高級副總裁,負責全國住房和醫院服務業務。根據新的僱傭協議,Maughan的年基本工資爲725,000美元,目標激勵獎金機會爲其2024年基本工資的100%。他將參與公司提供給高級管理人員的員工福利計劃和長期激勵計劃。該協議包括在無故解僱或有正當原因辭職的情況下的離職條款,包括基本工資繼續支付一年(如果在控制權變更後的兩年內因正當原因辭職,則延長至兩年)。在2006年加入德維特之前,Maughan在2001年至2004年期間曾在高盛的財務部門工作。
德維特宣佈任命David P. Maughan爲德維特腎臟護理的首席運營官,任命自2024年9月15日起生效,接替Michael D. Staffieri,後者將過渡爲名譽首席運營官。47歲的Maughan在2019年11月之前擔任腎臟護理的高級副總裁,負責全國住房和醫院服務業務。根據新的僱傭協議,Maughan的年基本工資爲725,000美元,目標激勵獎金機會爲其2024年基本工資的100%。他將參與公司提供給高級管理人員的員工福利計劃和長期激勵計劃。該協議包括在無故解僱或有正當原因辭職的情況下的離職條款,包括基本工資繼續支付一年(如果在控制權變更後的兩年內因正當原因辭職,則延長至兩年)。在2006年加入德維特之前,Maughan在2001年至2004年期間曾在高盛的財務部門工作。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息